Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast‐like synoviocytes

IUBMB Life - Tập 71 Số 7 - Trang 969-977 - 2019
Yunxia Tao1, Gaoran Ge1, Qing Wang1, Wei Wang1, Wenhao Zhang1, Jiaxiang Bai1, Jiayi Lin1, Jining Shen1, Xiaobin Guo1, Yaozeng Xu1, Dechun Geng1
1Department of Orthopedics, The First Affiliated Hospital of Soochow University, Suzhou, China

Tóm tắt

AbstractRheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease of unknown etiology characterized by degradation of cartilage and bone, accompanied by unimpeded proliferation of synoviocytes of altered phenotype. In the present study, we investigated the involvement of the glucagon‐like peptide 1 (GLP‐1) receptor on human fibroblast‐like synoviocytes (FLS) in the pathogenesis of RA using the selective GLP‐1 agonist exenatide, a licensed drug used for the treatment of type 2 diabetes. Our results indicate that exenatide may play a role in regulating tumor necrosis factor‐α‐induced mitochondrial dysfunction by increasing mitochondrial membrane potential, oxidative stress by reducing the production of reactive oxygen species, the expression of NADPH oxidase 4, expression of matrix metalloproteinase (MMP)‐3 and MMP‐13, release of proinflammatory cytokines including interleukin‐1β (IL‐1β), IL‐6, monocyte chemoattractant protein‐1, and high‐mobility group protein 1, as well as activation of the p38/nuclear factor of κ light polypeptide gene enhancer in B‐cells inhibitor, α/nuclear factor κB signaling pathway in primary human RA FLS. These positive results indicate that exenatide may have potential as a therapeutic agent for the treatment and prevention of RA. © 2019 IUBMB Life, 9999(9999):1–9, 2019

Từ khóa


Tài liệu tham khảo

10.1016/j.immuni.2017.02.006

10.1038/nrrheum.2016.69

10.1038/cddis.2016.490

10.1111/j.0105-2896.2009.00859.x

10.1093/rheumatology/ken086

10.1038/srep20059

10.5958/0974-360X.2017.00507.8

10.3389/fimmu.2018.02118

10.1002/art.10697

10.1016/j.cca.2016.02.010

10.1136/annrheumdis-2013-204543

10.1053/gast.2001.29035

10.1186/ar1447

10.1093/rheumatology/kel149

10.2147/DMSO.S130834

Yesil S., 2018, Exenatide reduces oxidative stress and cell death in testis in iron overload rat model, Exp. Ther. Med., 16, 4349

Tang Z., 2018, Exendin‐4 reverses endothelial dysfunction in mice fed a high‐cholesterol diet by a GTP cyclohydrolase‐1/tetrahydrobiopterin pathway, Mol. Med. Rep., 18, 3350

Chiquette E., 2012, Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers, Vasc. Health Risk Manag., 8, 621

10.1016/j.pharep.2018.10.003

10.7150/ijms.24492

10.1159/000373938

10.1007/s00011-006-6036-8

10.1371/journal.pone.0152925

10.1331/JAPhA.2009.09078

10.1007/s11883-008-0009-z

Fernandes J. C., 2002, The role of cytokines in osteoarthritis pathophysiology, Biorheology, 39, 237

10.1002/dmrr.538

Berenbaum F. Bougault C. andAttali C.(2017)U.S. Patent No. 9 592 272. Washington DC: U.S. Patent and Trademark Office.

10.1038/s41419-017-0217-y

Haack T. Wagner M. Henkel B. Stengelin S. Evers A. et al. (2017)U.S. Patent Application No. 14/569 326.

10.1007/s00223-009-9220-3

10.1210/jc.2015-1176

10.4103/0366-6999.170259

10.1074/jbc.M608083200

10.1152/ajpcell.2001.280.1.C53

Thông tin
Thông tin xuất bản

IUBMB Life

Tập 71 Số 7

969-977

Thông tin tác giả